drugset / Trial / NCT00218413
Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
Phase 2
Completed
51 enrolled
Nabi Biopharmaceuticals
National Institute on Drug Abuse (NIDA) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Nicotine is highly addictive and many individuals are unable to quit smoking even with treatment. The purpose of this study is to determine the effectiveness of various doses of NicVAX in treating nicotine dependent individuals.
Timeline
- Start
- 2004-10
- Primary completion
- 2006-08
- Completion
- 2006-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NicVAX | Vaccine | 100 ug | — |
| Subject | NicVAX | Vaccine | 200 ug | — |
| Subject | NicVAX | Vaccine | 300 ug | — |
| Subject | NicVAX | Vaccine | 400 ug | — |